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Introduction
Since the 1960s there has been a keen interest in how 
to direct a patient’s immune system to fight cancer. 
Autologous vaccines represent one of the earliest forms of 
immunotherapy studied, beginning with a rabbit model 
of viral-induced carcinoma.1 Autologous cancer vaccines 
(ACVs) represent a form of active immunotherapy in 
which antigenic material is derived from the patient’s 
own tumor.2 After ex vivo processing, tumor cells are 
returned to the patient with the goal of stimulating an 
immune response against multiple tumor antigens unique 
to the individual. A successful immune response involves 
cytotoxic T cells capable of recognizing tumor-associated 
antigens (TAAs) and tumor-specific antigens that may be 
abundantly expressed or unique to the patient.3 Various 
methods of tumor processing have been used to create 
ACVs, including whole-cell vaccines, tumor-cell lysates, 
isolation of specific intracellular components (eg, heat 
shock proteins [HSPs]) and transfection of cells to induce 
novel antigen presentation.4 Before being administered to 
the patient, the cancer cells are inactivated using chemi-
cal treatment, cell lysis or irradiation.5–7 Subcutaneous 
(SC), intramuscular (IM), intraperitoneal and intradermal 
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routes of administration of ACVs have been described in 
dogs.5,6,8,9 To date, ACVs have not been evaluated in cats.
As early as 1964 it was recognized that ACVs were 
capable of inducing a humoral immune response in 
human patients with terminal cancer.10 The method of 
tumor processing was also discovered to affect the TAAs 
available for presentation to the immune system, and 
various strategies were studied to chemically or enzy-
matically dissociate tumor cells to try and preserve the 
most TAAs.11 Early development of ACVs was slow given 
the rudimentary understanding of the immune system, as 
well as the paucity of available reagents and instrumenta-
tion. Through the late twentieth century, studies of ACVs 
were conducted in people with melanoma, colorectal car-
cinoma, head and neck squamous cell carcinoma (SCC), 
non-small-cell lung cancer and renal cell carcinoma, 
among others.12–18 The interest in ACVs has continued 
over the past 50 years in human oncology, with multiple 
ongoing human clinical trials describing some form of 
ACV listed on the ClinicalTrials.gov website.19
The development of ACVs in veterinary oncology 
has progressed more slowly than in human medicine. 
This is owing, in part, to the lack of validated reagents 
for studying the immune system in companion animals. 
As a result, there are only a handful of canine studies 
describing ACVs in the veterinary literature, including 
vaccines created from irradiated cancer cells transfected 
with human granulocyte–macrophage colony-stimulating 
factor, cancer cells transfected with the gene encoding 
Emm55, a Streptococcus pyogenes serotyping antigen, a 
whole-cell vaccine prepared using enzymatic cell dis-
sociation and an autologous vaccine consisting of HSPs 
isolated from the patient’s tumor with a hydroxylapatite 
ceramic powder adjuvant.9,20–22
Similarly, there are limited published safety data 
regarding ACVs in veterinary medicine. There were no 
significant adverse events (AEs) described in the stud-
ies discussed above.9,20–22 Additional evidence that this 
form of immunotherapy is safe for dogs comes from two 
recently published studies. The first report described 150 
IM injections of an adjuvanted autologous tumor lysate 
preparation to a group of 28 cancer-bearing dogs.6 No sig-
nificant AEs were reported. The second report described 
the AEs in 93 cancer-bearing dogs treated with an adju-
vanted whole-cell ACV, which is the same ACV used 
in the present feline study.5 Approximately 10% of the 
treated dogs developed mild AEs after vaccine admin-
istration. All of the described AEs were characterized as 
grade 1 (mild) on the Veterinary Comparative Oncology 
Group – Common Terminology Criteria for Adverse 
Events (VCOG-CTCAE) scale,23 and included redness 
or discomfort at the injection site, mild lethargy, tran-
sient decrease in appetite or low-grade fever. None of 
the described AEs required medical intervention and all 
resolved spontaneously.
To date, there have been no published reports of the 
use of active cancer immunotherapy with an ACV in cats. 
The purpose of this study was to determine the frequency 
and severity of AEs in cats treated with an adjuvanted 
whole-cell ACV that has been previously evaluated 
in dogs.5
Materials and methods
Autologous cancer vaccine protocol
After surgical excision, unfixed tumor tissue was placed 
into an empty, sterile container and shipped overnight 
on cold packs to the commercial laboratory (Torigen 
Pharmaceuticals, Farmington, CT, USA) for prepara-
tion of the ACV. The vaccine preparation has been 
described elsewhere.5 Briefly, the tumor tissue was 
mechanically dissociated into a uniform cell suspension, 
cells were inactivated with 2.5% glutaraldehyde and 
eventually combined with a protein matrix immuno- 
modulator adjuvant (MIM-SIS; Cook Biotech). The 
final vaccine product was placed into a sterile vial and 
shipped overnight on cold packs to the submitting vet-
erinarian for administration to the cat. Veterinarians 
were instructed to give 1 ml of the vaccine SC once every 
7 days for three total doses. The attending veterinarian 
was further instructed to monitor the cat for acute AEs for 
30 mins after each of the three injections. At hospital dis-
charge, cat owners were also informed of possible vaccine 
reactions and instructed to report any observed abnor-
malities immediately upon their occurrence. Written 
owner informed consent was obtained before the vac-
cine was produced and administered as required by the 
United States Department of Agriculture for unlicensed 
biologics.
Case selection
The case accession database at Torigen Pharmaceuticals 
was queried to identify cats treated with the adjuvanted 
whole-cell ACV between November 2015 and November 
2020. Cats were eligible for inclusion in this study if they 
had a histopathologic or cytologic diagnosis of cancer 
and received at least one dose of the vaccine. Cats were 
excluded from study if they had a histologic or cytologic 
diagnosis of a non-cancerous process, did not receive at 
least one dose of the adjuvanted whole-cell ACV, received 
adjuvant chemotherapy or radiation therapy concurrent 
with ACV treatment or had incomplete case information. 
Histopathologic and cytologic diagnoses were reported 
by board-certified veterinary pathologists via commercial 
laboratory services. Patient data collected included sig-
nalment, body weight, histology or cytology results and 
reported AEs following ACV administration. Details on 
AEs were collected from telephone or email contact with 
the cat owners and submitting veterinarians, or through 
a survey tool sent at regular intervals to each submitting 
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veterinarian. Follow-up information for each cat with a 
reported AE was obtained through direct communica-
tion with the submitting veterinarian and medical records 
were requested for affected cats. An AE was considered to 
be any observation in treated cats that was unfavorable, 
unintended and occurred after the use of the investiga-
tional veterinary product, whether or not it was consid-
ered to be product-related.24 AEs were classified based on 
the VCOG-CTCAE.23
Summary statistics were generated using commercial 
software (XLSTAT Life Science 2020; Addinsoft). Results 
are reported as mean ± SD unless otherwise noted.
Informed consent
Informed written consent was obtained from the owner 
or legal custodian of all animals described in this work 
for the procedures undertaken regarding the clinical use 
of the investigational, commercially available, autolo-
gous cancer vaccine as required by the United States 




There were 193 feline cases identified in the database. Of 
these cats, 61 (31.6%) did not receive any vaccine dose as a 
result of the owners or attending veterinarians opting for 
other treatment options, a non-cancerous diagnosis or the 
death of the patient before the vaccine could be adminis-
tered. One of these patients that was coded as a Bengal cat 
was actually a Bengal tiger and therefore excluded from 
study. An additional 15 (7.8%) cats that received at least 
one dose of the vaccine were excluded from the study 
owing to concurrent use of chemotherapy (n = 10), no 
pathology report provided by the attending veterinarian 
(n = 4) or non-cancerous process (n = 1).
During the 5-year study period, 438 doses of the adju-
vanted whole-cell ACV were administered to 117 cats that 
met the inclusion criteria. The mean number of vaccine 
doses administered per cat was 3.7 ± 3.29 (median 3.0; 
range 1–36). Eighteen (15.4%) cats were treated with >1 
course (ie, more than 3 doses) of the adjuvanted whole-
cell ACV during the study period, owing to cancer recur-
rence or the development of a new malignancy. Sixteen 
cats received six doses of the adjuvanted whole-cell ACV, 
one cat received 12 doses and one cat received 36 doses 
over the course of 4 years during the study period. The 
male:female ratio was approximately 1:1, and the major-
ity (71.8%) of cats were described as domestic shorthairs. 
Summary data are presented in Table 1.
Tumor specimens were submitted from cats in 26 dif-
ferent states, with the largest proportion of cases coming 
from Connecticut and Washington (Figure 1). General 
practitioners submitted 76 (65.0%) cases, and 41 (35.0%) 
cases were submitted by specialists (surgeons and 
medical oncologists). There were 48 (41.0%) epithelial 
tumors, 59 (50.4%) mesenchymal tumors and 10 (8.5%) 
discrete round-cell tumors. The most commonly submit-
ted epithelial tumors were mammary gland carcinomas 
(n = 19 [39.6%]) and SCCs (n = 7 [14.6%]). Soft tissue sar-
comas (n = 53 [86.9%]), of which 18 were described as 
injection-site sarcomas, represented the most commonly 
submitted mesenchymal tumor. Lymphoma was the most 
frequent round-cell tumor submission (n = 5 [50%]).
AEs
There were seven AEs reported in six (5.1%) cats, which 
were associated with six (1.4%) doses of the novel adju-
vanted whole-cell ACV. The most common AE was 
lethargy, reported in four cats. Of the reported AEs, six 
(85.7%) were characterized as mild or moderate (grade 
1 or 2), and there was only one severe (grade 5) AE 
reported. AEs were reported after the first adjuvanted 
whole-cell ACV dose in three (42.9%) cats, after the sec-
ond dose in two (28.6%) cats and after the third dose in 
one (14.3%) cat. One cat with an oral SCC had two AEs 
(lethargy and anorexia) reported after the second dose 
Table 1 Summary data from 117 cancer-bearing cats 
treated with surgery and an adjuvanted whole-cell 
autologous cancer vaccine (ACV)
Variable  
Age (years) 11.1 ± 3.33
 Range 3.0–19.9
Weight (kg) 5.1 ± 1.70
 Range 1.8–13.4
Sex  
 Male 58 (49.6)
 Female 59 (50.4)
Reproductive status  
 Neutered 114 (97.4)
 Intact 3 (2.6)
Breed  
 Domestic shorthair 84 (71.8)
 Domestic longhair 13 (11.1)
 Maine Coon 4 (3.4)
 Other breeds 16 (13.7)
Cancer origin  
 Epithelial 48 (41.0)
 Mesenchymal 59 (50.4)
 Round cell 10 (8.5)
Doses of Torigen ACV administered 438
 Doses per cat 3.7 ± 3.29
 Range 1–36
AEs 7
 Affected cats 6 (5.1)
 Doses associated with AEs 6 (1.4)
 Doses associated with serious AEs 1 (0.2)
Data are n (%) or mean ± SD
AEs = adverse events
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of the vaccine; there were no reported AEs with the first 
or third doses, nor with three additional doses given 2 
months after the initial series owing to local tumor pro-
gression. The remaining 15 cats treated with more than 
three doses of the adjuvanted whole-cell ACV had no 
reported AEs. Regarding the attribution of reported AEs 
to the adjuvanted whole-cell ACV, one (14.3%) was classi-
fied as unrelated, two (28.6%) were classified as unlikely, 
two (28.6%) were classified as possible and two (28.6%) 
were classified as probable.
The AE that was classified as unrelated, which was 
also the only severe AE, was reported in a cat with meta-
static pulmonary carcinoma. The cat died at home 3 days 
after the first dose of the vaccine. Necropsy revealed pleu-
ral effusion, carcinomatosis and effacement of pulmo-
nary tissue by neoplastic cell, making cancer the probable 
cause of death. For the two AEs considered unlikely to 
be related to the novel adjuvanted whole-cell ACV, the 
first was fever following the first dose of vaccine in a cat 
with laryngeal lymphoma. The cat owner was keeping 
the cat on an electric heating pad at the time the fever was 
reported, and the cat also suffered second-degree burns 
on the ventral body wall. The elevated body temperature 
was thought to be a result of exposure to the heating pad. 
The second AE unlikely to be related to the vaccine was 
lethargy, which was reported after the third dose in a 
cat with mammary carcinoma. An infection was concur-
rently diagnosed at the mastectomy incision site, which 
was likely the cause of the observed lethargy.
The two AEs that were classified as possibly related 
to the vaccine were reported in the cat with oral SCC 
described above. The two AEs that were classified 
as probable were reported in a cat with osteosarcoma 
shortly after the second vaccine dose, and in a cat with 
an injection-site swelling several hours after the first dose.
Discussion
For consistency with previously published safety and effi-
cacy data in dogs treated with this ACV,5,25 cats described 
herein were also given a series of three SC injections 
spaced 1 week apart. The most effective interval for ACV 
administration remains unknown. Rodent data on the 
effect of dosing interval on efficacy are limited; studies 
that are available often do not detail which intervals are 
best to produce an immune response. A recent study in 
mice revealed that three doses of an autologous vaccine 
generated a superior immune response and better tumor 
control, compared with mice treated with either one or 
five doses.26 Given the heterogeneity of ACV products, 
and a lack of conclusive mouse model data, it is difficult 
to extrapolate mouse model results to an effective dosing 
scheme in feline patients. In a study of an ACV given IM 
to dogs, no significant difference in AE rates was found 
between dogs receiving four weekly administrations 
and a group treated with four doses given at 4-week 
intervals.6 Presently, there is no consensus on the optimal 
dosing interval for ACVs in humans, in part, owing to a 
comparative lack of data on clinically successful autolo-
gous vaccines relative to infectious disease vaccines.27
The population of cats described herein was geo-
graphically diverse, and the observed middle age of the 
affected cats was similar to previous reports.28,29 The 
Figure 1 Geographic distribution of 117 cats treated with an adjuvanted whole-cell autologous cancer between November 
2015 and November 2020
Lucroy et al 5
predominance of mesenchymal tumors within this popu-
lation is different than the majority of epithelial tumors 
described in a review of the Swiss Feline Cancer Registry.29 
This may reflect the smaller population size herein, or be 
a result of the different genetic make-up of cats in the USA 
vs Switzerland. This could also represent case selection 
bias by the submitting veterinarians, if cat owners opt 
out of postoperative radiation therapy for managing soft 
tissue sarcomas; round-cell tumors and carcinomas have 
a wider array of available adjuvant treatment options. 
Likewise, a higher risk of female cats developing cancer 
was observed in the Swiss Feline Cancer Registry;28 that 
finding was not replicated here. Unfortunately, there are 
no contemporary feline cancer registries in the USA to 
allow for comparison of breed distribution.
The cancer-bearing cats treated with immunotherapy 
in this study all tolerated the novel adjuvanted whole-
cell ACV well, with a few, mild AEs described. The AE 
rate in the group of cats described herein was even lower 
than previously reported in 93 dogs (11.8%),5 as well as 
a group of 28 horses (14.3% [MD Lucroy, unpublished 
data]) treated with the same ACV.
Given the retrospective nature of this study, and the 
potential for veterinarians or cat owners to not report 
observed AEs, it is possible that the observed AE rate 
could be lower than the actual rate. However, ACVs 
detailed in the human literature have a consistently 
reported low rate of AEs. In a human study of an ACV 
modified genetically with tag7/PGRP-S, none of the 
patients demonstrated any clinical significant signs of 
toxicity.30 Additional studies of ACVs in humans with 
solid tumors have reported a similar lack of AEs or clini-
cally significant events, with the worst AEs being infre-
quent and limited to grade 1/2 AEs.31,32 Moreover, the 
adjuvant (MIM-SIS) used in the ACV studied here is a 
non-irritating adjuvant that has a very low incidence 
of AEs, while also being capable of producing a robust 
immune response against co-administered antigens.33,34 
Based on the reported safety of autologous cancer vac-
cines among various species, and the properties of MIM-
SIS, the low AE rate reported in this population of cats 
is likely representative of what could be expected with 
more widespread use.
Only one of the 18 cats that received more than three 
doses of the novel adjuvanted whole-cell ACV during 
the study period was reported to have an AE. This was 
an episode of mild lethargy following the second vac-
cine dose. No AEs were reported following the other five 
doses. Sixteen cats received six doses of the novel adju-
vanted whole-cell ACV, one cat received 12 doses and 
one cat received 36 doses during the 5-year study period, 
demonstrating that repeated exposure over time does not 
appear to increase the risk of an AE.
Although chemotherapy is a commonly used adjuvant 
treatment after cancer surgery, many cat owners are con-
cerned about AEs associated with chemotherapy. A study 
of pet owners revealed that 58% would not pursue chem-
otherapy citing concerns about the risk for AEs.35 This is 
not an unfounded fear. Neutropenia is most commonly 
the dose-limiting AE, and vomiting and diarrhea are com-
monly reported, with cats being particularly sensitive to 
diminished appetite and weight loss.36 In a population 
of 70 cats treated with doxorubicin, alone or as part of 
a combination chemotherapy protocol, 34% had at least 
one episode of neutropenia, 44% were anemic and 29% 
developed acute kidney injury.37 Appetite decrease, vom-
iting and diarrhea were also reported in 13%, 16% and 
7% of instances, respectively, where recorded. Similarly, 
a retrospective study of cats with mast cell cancers treated 
with oral toceranib phosphate (Palladia; Zoetis) had 
a reported AE rate of 60%, including gastrointestinal 
and hematologic events, which necessitated a break in 
treatment.38 Therefore, the adjuvanted whole-cell ACV 
used in the present study may represent an appealing 
option for cat owners concerned about potential risks 
associated with chemotherapy. Until efficacy data regard-
ing this ACV are published, it will be impossible for vet-
erinarians and cat owners to assess the risk:benefit ratio 
when making treatment decisions.
The strengths of the study include the large number 
of cats described herein that received >400 doses of the 
ACV, and that the reported observations represent the 
experience from typical use in the field. These results 
are valuable for veterinarians when discussing cancer 
treatments with cat owners. Including owner-reported 
AEs provides additional information not readily avail-
able from a medical record review. In human medicine, 
patient reports of AEs have been shown to be a credible 
source of information for care-related AEs.39 A limitation 
of this study is the retrospective nature of case reviews.
Given the low rate of AEs described in this population 
of 117 cats under field conditions, and the previous report 
describing a low rate of AEs in a population of 93 simi-
larly treated dogs at a single surgery practice,5 this adju-
vanted whole-cell ACV appears to be a comparatively 
safe cancer treatment. Further studies are warranted to 
determine the efficacy of this form of active immuno-
therapy in cancer-bearing cats.
Conclusions
AEs were infrequent in the population of cats treated with 
an adjuvanted whole-cell ACV. This form of active can-
cer immunotherapy appears to be well tolerated by cats 
and may represent an alternative treatment for owners 
who are concerned about AEs associated with chemother-
apy or radiotherapy. Additional studies are warranted 
to determine the efficacy of this form of individualized 
immunotherapy in cats with solid tumors.
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